Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US PTO has issued a notice of allowance to Vanda Pharmaceuticals (Vanda) for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product Fanapt (iloperidone).
Subscribe to our email newsletter
The US patent is expected to expire on October 30, 2022 and, in addition, the US PTO has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.
The oral formulation is marketed in the US under the tradename Fanapt by Novartis Pharmaceuticals pursuant to an agreement between Vanda and Novartis Pharma, which was entered into on October 12, 2009.
Reportedly, Novartis is responsible for the commercialisation and further clinical development activities of Fanapt in the US and Canada, including the development and commercialisation of the long-acting injectable (or depot) formulation of Fanapt. Vanda retains rights to commercialise Fanapt oral and depot formulations outside the US and Canada.